|Bid||4.1700 x 800|
|Ask||4.1800 x 1100|
|Day's range||4.0600 - 4.2700|
|52-week range||3.7000 - 36.0000|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||18 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investors who take an interest in Virpax Pharmaceuticals, Inc. ( NASDAQ:VRPX ) should definitely note that the Chairman...
BERWYN, Pa., November 15, 2021--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments.
BERWYN, Pa., November 10, 2021--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, today announced that the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) has awarded research and development contracts to support Good Manufacturing Practices (GMP) production of drug substance and drug product. as wel